Plasma exchange significantly affects darunavir exposure.
Infectious Diseases Department, University Hospital of Poitiers, Poitiers, France.
Magali
M
Garcia
Infectious Diseases Department, University Hospital of Poitiers, Poitiers, France.
Gwenaël
G
Le Moal
Pharmacy Department and UMR CNRS 7285, University Hospital of Poitiers, Poitiers, France.
Antoine
A
Dupuis
Etablissement Français du Sang, Poitiers, France.
Nathalie
N
Rochette
Infectious Diseases Department, University Hospital of Poitiers, Poitiers, France INSERM U1070, Pole Biologie Santé, Poitiers, France.
France
F
Roblot
Pharmacokinetics Department, University Hospital of Poitiers, Poitiers, France nicolas.venisse@chu-poitiers.fr.
Nicolas
N
Venisse
D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D000069454:Darunavir; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D010951:Plasma Exchange / Q000009:adverse effects*; D019438:Ritonavir / Q000627:therapeutic use; D013449:Sulfonamides / Q000097:blood* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019562:Viral Load
D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D019438:Ritonavir; D000069454:Darunavir
HIV protease inhibitors; apheresis; pharmacokinetics